Michael Heltzen is listed as an executive officer and director on 4 SEC Form D filings by 3 issuers between Apr 2019 and Nov 2024: Cardea Bio, Inc. (San Diego, CA — other technology — 2019–2020; $7.4M reported sold to 54 investors), CRISPRQC INC. (San Diego, CA — biotechnology — 2022; $3.89M reported sold to 14 investors) and Invizyne Technologies Inc (Monrovia, CA — biotechnology — 2024; $12K reported sold to 2 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 5 years. Across those companies the filings report $11.3M sold in total.
Listed alongside Ross Bundy (2 shared filings), Tim Hoerr (2 shared filings), Anthony DiGiandomenico (1 shared filing), Biao He (1 shared filing), Brett Goldsmith (1 shared filing) and 10 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Michael Heltzen and found 3 differences: Form D filed 19 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.